- In October 2023, Labcorp launched a tri-biomarkers blood test aimed at improving the diagnosis of Alzheimer’s disease by detecting multiple biomarkers simultaneously. This advancement could enable earlier and more accurate diagnosis, supporting better treatment planning and patient care
- In October 2023, Mindray introduced high-sensitivity NT-proBNP and troponin I (hs-cTnI) cardiac biomarkers to its product lineup. These tests enhance the detection and management of cardiovascular diseases by providing more precise and timely diagnostic information
- In August 2023, Quest Diagnostics partnered with Envision Sciences to commercialize a novel prostate cancer biomarker test. This test helps identify severe and aggressive forms of prostate cancer, aiding clinicians in making more informed treatment decisions
- In February 2023, Cardio Diagnostics Holdings Inc. launched PrecisionCHD, an epigenetic-genetic blood test designed for early diagnosis of coronary heart disease. The test offers the potential for proactive disease management through early detection and risk stratification
- In August, 2022: Thermo Fisher Scientific, Inc. launched CE-IVD (IVDD) NGS test and analysis software to expand access to personalized oncology biomarker testing. This announcement underscores the company's commitment to advancing the accessibility and accuracy of molecular diagnostics for cancer patients. The CE-IVD certification is a crucial regulatory milestone, indicating that the NGS test and associated software meet the rigorous standards required for diagnostic use in Europe. This certification ensures the reliability and consistency of the test results, making them suitable for clinical decision-making
